Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists

• Autor(a) principal: Rosário,Pedro W.
• Data de Publicação: 2010
• Outros Autores: Purisch,Saulo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302010000600006
• topic: Acromegaly; prolactinoma; growth hormone; IGF-1

OBJECTIVE: To evaluate the frequency of subclinical acromegaly (in the absence of clinical phenotype but biochemically uncontrolled) in patients with prolactinoma during treatment with dopaminergic agonists. SUBJECTS AND METHODS: One hundred twenty one patients without a phenotype suggestive of acromegaly were studied. RESULTS: Initially, the laboratory diagnosis of acromegaly was unequivocal (elevated IGF-1 for gender and age with nadir GH &gt; 1 μg/L) in two patients, and likely (elevated IGF-1 with nadir GH &gt; cut-off but < 1 μg/L) in another patient. In two other patients, this diagnosis was possible (normal IGF-1 with nadir GH &gt; 1 μg/L). Repetition of the tests 6 months after withdrawal of the dopaminergic agonist confirmed the diagnosis of subclinical acromegaly (elevated IGF-1 for gender and age with nadir GH &gt; 1 μg/L) in these 5 patients. False-positive results were excluded in all cases. CONCLUSION: In patients with prolactinomas, acromegaly should be investigated not only in cases with a clinical phenotype.